Assessment of voluntary ethanol consumption and the effects of a melanocortin (MC) receptor agonist on ethanol intake in mutant C57BL/6J mice lacking the MC-4 receptor.

Navarro M, Lerma-Cabrera JM, Carvajal F, Lowery EG, Cubero I, Thiele TE

Alcoholism, clinical and experimental research17 Feb 2011Cited by 30 (Europe PMC)

PMID21332528PMCIDPMC3097291DOI10.1111/j.1530-0277.2011.01438.xPepBankPUB-21332528

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In wild-type Mc4r(+/+) mice, intracerebroventricular MTII significantly reduced ethanol drinking.
In plain wordsIn mice, Melanotan II given into the brain reduced alcohol drinking.
Peptide
Melanotan II
Outcome
DecreaseEthanol drinking, i.c.v. MTII, wild-type mice
Study
mousen: not reported in source
C57BL/6J Mc4r knockout and wild-type mice
Comparator
Vehicle (MTII 0)
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.5 or 1.0 ug/1 ul · intracerebroventricularAs given in this study (mouse).
Source sentences
Summary
I.c.v. infusion of MTII significantly reduced ethanol drinking in Mc4r(+/+) mice
2 context sentences(design, population, supporting numbers)
Summary · context
In separate experiments, Mc4r(-/-) and Mc4r(+/+) mice were given intracerebroventricular (i.c.v.) infusion of MTII (0, 0.5, or 1.0 μg/1 μl) or intraperitoneal (i.p.) injection of MTII (0 or 5 mg/kg/5 ml).
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252801
02AnimalAnimal study (in vivo)Efficacy outcome
In Mc4r(-/-) mice, intracerebroventricular MTII did not change ethanol intake.
In plain wordsIn mice without the MC4 receptor, Melanotan II given into the brain did not change alcohol drinking.
Peptide
Melanotan II
Outcome
No significant changeEthanol drinking, i.c.v. MTII, Mc4r knockout mice
Study
mousen: not reported in source
C57BL/6J Mc4r knockout and wild-type mice
Comparator
Vehicle (MTII 0)
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.5 or 1.0 ug/1 ul · intracerebroventricularAs given in this study (mouse).
Source sentences
Summary
but failed to influence ethanol intake in Mc4r(-/-) mice.
2 context sentences(design, population, supporting numbers)
Summary · context
In separate experiments, Mc4r(-/-) and Mc4r(+/+) mice were given intracerebroventricular (i.c.v.) infusion of MTII (0, 0.5, or 1.0 μg/1 μl) or intraperitoneal (i.p.) injection of MTII (0 or 5 mg/kg/5 ml).
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252802
03AnimalAnimal study (in vivo)Efficacy outcome
In Mc4r(-/-) mice, intraperitoneal MTII significantly reduced ethanol drinking.
In plain wordsIn mice without the MC4 receptor, Melanotan II injected into the belly cavity reduced alcohol drinking.
Peptide
Melanotan II
Outcome
DecreaseEthanol drinking, i.p. MTII, Mc4r knockout mice
Study
mousen: not reported in source
C57BL/6J Mc4r knockout and wild-type mice
Comparator
Vehicle (MTII 0)
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
5 mg/kg/5 ml · intraperitonealAs given in this study (mouse).
Source sentences
Summary
When administered in an i.p. injection, MTII significantly reduced ethanol drinking in both Mc4r(-/-) and Mc4r(+/+) mice.
2 context sentences(design, population, supporting numbers)
Summary · context
In separate experiments, Mc4r(-/-) and Mc4r(+/+) mice were given intracerebroventricular (i.c.v.) infusion of MTII (0, 0.5, or 1.0 μg/1 μl) or intraperitoneal (i.p.) injection of MTII (0 or 5 mg/kg/5 ml).
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252803
04AnimalAnimal study (in vivo)Efficacy outcome
In Mc4r(+/+) mice, intraperitoneal MTII significantly reduced ethanol drinking.
In plain wordsIn mice, Melanotan II injected into the belly cavity reduced alcohol drinking.
Peptide
Melanotan II
Outcome
DecreaseEthanol drinking, i.p. MTII, wild-type mice
Study
mousen: not reported in source
C57BL/6J Mc4r knockout and wild-type mice
Comparator
Vehicle (MTII 0)
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
5 mg/kg/5 ml · intraperitonealAs given in this study (mouse).
Source sentences
Summary
When administered in an i.p. injection, MTII significantly reduced ethanol drinking in both Mc4r(-/-) and Mc4r(+/+) mice.
2 context sentences(design, population, supporting numbers)
Summary · context
In separate experiments, Mc4r(-/-) and Mc4r(+/+) mice were given intracerebroventricular (i.c.v.) infusion of MTII (0, 0.5, or 1.0 μg/1 μl) or intraperitoneal (i.p.) injection of MTII (0 or 5 mg/kg/5 ml).
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252804
05AnimalAnimal study (in vivo)Efficacy outcome
In C57BL/6J mice, MTII attenuated consumption of 10% sucrose.
In plain wordsIn mice, Melanotan II reduced sugar-water drinking.
Peptide
Melanotan II
Outcome
DecreaseSucrose intake
Study
mousen: not reported in source
C57BL/6J mice
Comparator
Vehicle (MTII 0)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.5 ug/1 ul · intracerebroventricularAs given in this study (mouse).
Source sentences
Summary
MTII attenuated consumption of caloric (ethanol, sucrose
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of MTII (0 or 0.5 μg/1 μl, i.c.v.) on 10% sucrose and 0.15% saccharin intake were assessed in C57BL/6J mice.
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252805
06AnimalAnimal study (in vivo)Efficacy outcome
In mice, MTII attenuated food consumption.
In plain wordsIn mice, Melanotan II reduced food eaten.
Peptide
Melanotan II
Outcome
DecreaseFood intake
Study
mousen: not reported in source
C57BL/6J Mc4r knockout and wild-type mice
Comparator
Vehicle (MTII 0)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
MTII attenuated consumption of caloric (ethanol, sucrose, and food)
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252806
07AnimalAnimal study (in vivo)Efficacy outcome
In C57BL/6J mice, MTII attenuated consumption of the noncaloric reinforcer saccharin (0.15%).
In plain wordsIn mice, Melanotan II reduced drinking of a calorie-free sweet solution.
Peptide
Melanotan II
Outcome
DecreaseSaccharin intake
Study
mousen: not reported in source
C57BL/6J mice
Comparator
Vehicle (MTII 0)
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.5 ug/1 ul · intracerebroventricularAs given in this study (mouse).
Source sentences
Summary
MTII attenuated consumption of caloric (ethanol, sucrose, and food) and noncaloric (saccharin) reinforcers
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of MTII (0 or 0.5 μg/1 μl, i.c.v.) on 10% sucrose and 0.15% saccharin intake were assessed in C57BL/6J mice.
Summary · context
To assess the role of the MC4R, MC4R knockout (Mc4r(-/-) ) and littermate wild-type (Mc4r(+/+) ) mice on a C57BL/6J background were used.
Report a problemFND-2133252807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.